Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) was conceived and initiated in 1995 as a collaboration between principal investigators of all the major ongoing clinical trials of BP lowering agents.

Individual participant data meta-analyses of large-scale blood pressure lowering trials

The Blood Pressure Lowering Treatment Trialists’ Collaboration (BPLTTC) was conceived and initiated in 1995 as a collaboration between principal investigators of all the major ongoing clinical trials of BP lowering agents. The aim of this novel initiative was to generate a strong evidence base for the effect of pharmacological BP (BP) lowering on major cardiovascular outcomes.    

The BPLTTC has successfully completed two phases (cycles) of investigations so far, which have provided reliable evidence for the substantial benefits of BP lowering for preventing major cardiovascular outcomes (coronary heart disease, heart failure and stroke) and have demonstrated that major classes of anti-hypertensives have similar benefits for the prevention of major vascular outcomes.

The findings from these analyses have been published in international journals such as the Lancet (Turnbull 2003; Turnbull et al. 2007; Sundström et al. 2014; Neal et al. 2000; BP Lowering Treatment Trialists’ Collaboration et al. 2014; BP Lowering Treatment Trialists’ Collaboration et al. 2015), BMJ (Turnbull et al. 2008; BP Lowering Treatment Trialists’ Collaboration et al. 2013) and Annals of Internal medicine, have been cited in academic/clinical books, and importantly have had a major influence on clinical practice guidelines informing clinical care worldwide.    

There remain, however, significant uncertainties on the benefits and risks of BP lowering beyond the effects on common major vascular outcomes. More specifically, little is known on the effect of lowering BP by important baseline characteristics of patients, on safety outcomes (e.g., cancer, falls and fractures, acute kidney injury), non-vascular outcomes (e.g., new-onset diabetes, dementia), and less commonly reported vascular outcomes (e.g., atrial fibrillation, peripheral arterial disease, aortic aneurysms, pulmonary embolism, stroke subtype).    

With access to individual participant data (IPD) from over 250,000 patients, the third BPLTTC cycle provides a unique opportunity to investigate these questions, with significant impact on public health and clinical practice.

Training opportunities

The project is suitable for a student with medical training or an epidemiologist with an interest in IPD meta-analyses and cardiovascular medicine.  The training opportunities include epidemiology, systematic literature review and statistical methods for IPD meta-analysis.    

The George Institute provides an exceptional educational environment with expert individual supervision and support from several of experienced and enthusiastic researchers with backgrounds in clinical medicine, statistics, epidemiology and engineering. 

Supervisor

Professor Kazem Rahimi

funding opportunities

None available.